Home / Latest News

Latest News

UK Marketing Authorisation Granted for Rosemont Glycopyrronium Bromide 1mg/5ml Oral Solution

On December 1st Rosemont Pharmaceuticals received Marketing Authorisation for Glycopyrronium Bromide 1mg/5ml Oral Solution. This prescription only medicinal product is indicated for symptomatic treatment of severe sialorrhoea (chronic pathological drooling) in children and adolescents aged 3 years and older with chronic neurological disorders. Sialorrhoea, or chronic pathological drooling, is the unintentional loss of saliva from the mouth and is most commonly caused by neuromuscular conditions.

Terms of Use | Privacy Policy |Cookie Preferences